Skip to content

UroGen Pharma URGN Change in AP

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Pfizer logo
PfizerPFE
-$117.25M+54.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$3.92B-84.4%
Merck & Co. logo
Merck & Co.MRK
$27.5M-39.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.9M-39.4%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$1.2M+427%

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%
Enterprise value$1.81B+80.9%
P/S12.3×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's change in AP?
UroGen Pharma (URGN) reported change in AP of $7.63M in Q1 2026.
How has UroGen Pharma's change in AP changed year-over-year?
UroGen Pharma's change in AP increased by 163.9% year-over-year, from $2.89M to $7.63M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.